Tests JS212 combinations in adults with advanced lung cancer

Who can take part

• The age between 18 and 75 years old, and any gender
• Local advanced, metastatic or recurrent NSCLC
• ES-SCLC
• According to the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), there must be at least one measurable lesion
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
• Expected survival period of ≥ 12 weeks
• The functions of important organs meet the requirements
• Female participants with reproductive capacity (WOCBP) who have sexual life with an unsterilized male partner and who have signed the informed consent must have a negative serum pregnancy test result within 7 days before the first administration, and must agree to take effective contraceptive measures from the time of signing the ICF until 7 months after the last administration of the study
• Unsterilized male participants who have sexual life with a fertile female partner must agree to use the effective contraceptive measures after signing the ICF until 4 months after the last administration of the study. During this period, sperm donation is prohibited
• The participants voluntarily participate in this study and sign the informed consent

Who cannot take part

• Within one month before the first use of the study drug, any clinically significant hemoptysis or tumor bleeding
• Have used antiplatelet drugs or anticoagulant therapy within 14 days
• Have experienced a drug-related adverse event that led to permanent discontinuation of the medication during previous Bevacizumab and similar agent treatments
• Have received any of the following treatments:
• Have received any investigational drug within 4 weeks or 5 half-lives before the first use of the study drug
• Have undergone major surgery within 4 weeks
• Have received local small-scale radiotherapy within 14 days; 4.Have not recovered to ≤ CTCAE grade 1 toxicity or the level specified in the inclusion/exclusion criteria; 5.Have known allergies to any study treatment or its excipients or have experienced an allergic reaction; 6.Have experienced a drug-related AE that led to permanent discontinuation of the anti-PD-(L)1 antibody treatment; 7.Have any of the following cardiac examination results:
• Uncontrolled concurrent diseases
• Accompanying the following disease states:
• Tumor histological or cytological pathological confirmation of combined large cell neuroendocrine carcinoma or sarcomatoid lesion, or NSCLC with small cell lung cancer component
• Participants in Cohort 1 and Cohort 4 need to exclude any of the following conditions:
• High bleeding risk; tumor invading important organs, high risks of perforation, esophageal-tracheal fistula, massive hemoptysis, etc
• Obvious bleeding tendency or severe coagulation dysfunction history, etc
• Recent gastrointestinal perforation, gastrointestinal obstruction, trachea-esophageal fistula, abdominal fistula or intra-abdominal abscess, or currently having high-risk factors for hollow organ perforation/ fistula formation, or active inflammatory bowel disease, etc
• Have poorly controlled hypertension
• Participants who were diagnosed with any other malignant tumor within 5 years
• Other conditions for trial participation were not considered appropriate by the investigator
• Long QT
• Left ventricular ejection fraction (LVEF) < 50%; 8.Have a history of diagnosed or suspected ILD, drug-induced pneumonia, or other severe lung diseases; 9.Have experienced a severe infection within 4 weeks; 10.Have a history of immunodeficiency, or have a history of organ transplantation and allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation; 11.Have active pulmonary tuberculosis infection; 12.Have active hepatitis
• NSCLC patients with positive driver mutations
• Patients with known meningeal metastasis
• Patients with symptomatic brain metastases
• Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites
• Unatable spinal cord compression
• Presence of severe, non-healed or open wounds, active ulcers or untreated fractures
• Immune-mediated treatments (only for part Two)
• Have been enrolled in another clinical study
• Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period